LYNPARZA™ APPROVED IN THE EUROPEAN UNION

LYNPARZA™ approved IN THE EUROPEAN UNION as FIRST-IN-CLASS treatment for
ADVANCED BRCA-MUTATED OVARIAN CANCER

AstraZeneca today announced that the European Commission (EC) has granted
Marketing Authorisation for Lynparza™ (olaparib) capsules (400mg twice daily) as
the first therapy for the maintenance treatment of adult patients with platinum
-sensitive relapsed BRCA-mutated (germline and/or somatic) high grade serous
epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in
complete response or partial response to platinum-based chemotherapy.

Olaparib is a poly ADP-ribose polymerase (PARP) inhibitor that exploits tumour
DNA repair pathway deficiencies to preferentially kill cancer cells. It is the
first PARP inhibitor to be approved for patients with platinum-sensitive
relapsed BRCA-mutated ovarian cancer. Patients will be identified through a
validated diagnostic test.

"We are delighted to be able to bring this much needed treatment to patients
with BRCA-mutated ovarian cancer whose options are currently very limited.
Today's approval marks a significant milestone in the development of the next
generation of targeted medicines," said Briggs Morrison, Executive Vice
President, Global Medicines Development and Chief Medical Officer at
AstraZeneca. "We are committed to bringing new treatments to the patients who
need them most and today's news marks only the first of what we hope will be a
number of indications in which Lynparza has the potential to transform the lives
of cancer patients, including those with breast, pancreatic and gastric
cancers."

The EC decision is applicable to all 28 EU member states as well as Norway,
Iceland and Liechtenstein. The approval of olaparib was based on data from Study
191, a Phase II clinical trial that evaluated its efficacy and safety compared
to placebo in platinum-sensitive relapsed high grade serous ovarian cancer
patients. The study showed that olaparib maintenance therapy significantly
prolonged progression free survival (PFS) compared with placebo in patients with
BRCA-mutated ovarian cancer: median PFS 11.2 months vs 4.3 months (PFS Hazard
Ratio = 0.18; 95% Confidence Interval 0.10-0.31; p<0.0001). The most common
adverse events associated with olaparib monotherapy to date were generally mild
to moderate and included nausea, vomiting, fatigue and anaemia.

Professor Steve Jackson, scientist at the University of Cambridge, whose
research established the basis for olaparib and its clinical potential said: "It
is wonderful to learn that olaparib is set to become a licensed drug and will
therefore soon become available to advanced ovarian cancer sufferers. I also
look forward to learning the results of ongoing trials exploring olaparib's
potential for the treatment of other cancers. Today's announcement highlights
how, by collaborating with a partner such as AstraZeneca, basic academic
research, such as that carried out by the research team at the University of
Cambridge, can lead to major medical developments."

"It is fantastic news that Lynparza will now be available for women with
advanced relapsed BRCA-mutated ovarian cancer," said Dr John Green, Senior
Lecturer, Institute of Translational Medicine, University of Liverpool and
Chair, European Network of Gynaecological Cancer Advocacy Groups (ENGAGe). "This
is a devastating disease which has a profound impact on patients and their
families. Women with a BRCA mutation are especially at risk and there has been a
significant need for new treatment options with novel modes of action. The
development of a targeted treatment like Lynparza is an excellent example of
pioneering research being translated into a treatment that has the potential to
transform the lives of patients."

1Ledermann J et al. Olaparib maintenance therapy in patients with platinum
-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis
of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncology. 2014.
15:852-861.

Additional commentary

Harpal Kumar, chief executive of Cancer Research UK, said: "It's great news that
the European Commission has approved the use of olaparib within the European
Union, especially when Cancer Research UK scientists played a crucial role in
discovering and developing this new generation of cancer drugs. This drug offers
new hope to women with advanced ovarian cancer by targeting the weaknesses
cancer cells have in repairing damaged DNA. With clinical trial results showing
this treatment has potential in other types of cancer, we hope there will be
more good news in the future. Our partnerships with AstraZeneca are helping us
to bring more new treatments to patients, accelerating our efforts to beat
cancer sooner."

About Lynparza™ (olaparib)

Olaparib is an innovative, first-in-class oral poly ADP-ribose polymerase (PARP)
inhibitor that exploits tumour DNA repair pathways deficiencies to
preferentially kill cancer cells. This mode of action gives olaparib the
potential for activity in a range of tumour types with DNA repair deficiencies.

In addition to ovarian cancer, AstraZeneca will investigate the full potential
of olaparib in multiple tumour types, with Phase III studies in second line
gastric cancer, BRCA-mutated pancreatic cancer and adjuvant and metastaticBRCA
-mutated breast cancers underway.

About ovarian cancer

In Europe, ovarian cancer is the fifth most commonly diagnosed cancer in women
and the sixth leading cause of cancer death among women, mainly because it is
often diagnosed late by which time the patient has an extremely poor prognosis.
For the 61% of ovarian cancer patients whose cancer has metastasised by the time
of diagnosis, the five-year survival rate is only 27%.

Up to 15% of women with ovarian cancer have a BRCA mutation, which is the most
common cause of homologous repair deficiency. In BRCA-mutated tumour cells,
homologous recombination is defective and DNA double-strand break repair is
forced to occur via error-prone pathways, which can lead to genomic instability
and cell death.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that
focuses on the discovery, development and commercialisation of prescription
medicines, primarily for the treatment of cardiovascular, metabolic,
respiratory, inflammation, autoimmune, oncology, infection and neuroscience
diseases. AstraZeneca operates in over 100 countries and its innovative
medicines are used by millions of patients worldwide. For more information
please visit: www.astrazeneca.com

CONTACTS

Media Enquiries

Esra Erkal-Paler  +44 20 7604 8030 (UK/Global)
Vanessa Rhodes    +44 20 7604 8037 (UK/Global)
Ayesha Bharmal    +44 20 7604 8034 (UK/Global)
Jacob Lund        +46 8 553 260 20 (Sweden)

Investor Enquiries

Thomas Kudsk Larsen  +44 20 7604 8199    mob: +44 7818 524185
Karl Hård            +44 20 7604 8123    mob: +44 7789 654364
Eugenia Litz         +44 20 7604 8233    mob: +44 7884 735627
Christer   Gruvris   +44   20 7604 8126  mob:   +44 7827 836825

18 December 2014

-ENDS-